I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DexCom Inc. Reports Fourth Quarter and Full Year 2010 Financial Results
Date : 03/03/2011 @ 4:01PM
Dexcom (NASDAQ:DXCM)
DexCom, Inc. (Nasdaq:DXCM) today reported its audited financial results as of and for the quarter and fiscal year ended December 31, 2010.
For the full-year ended December 31, 2010, product revenue grew to $40.2 million, an increase of 123% from the $18.0 million in product revenue reported for 2009, and total revenue grew to $48.6 million, an increase of 64% from 2009. Product revenue totaled $13.6 million for the fourth quarter of 2010, an increase of 105% from the $6.6 million in product revenue reported for the comparable period in 2009. Total fourth quarter 2010 revenue, which included development grant and other revenue, was $15.6 million, an increase of 49% from the comparable period in 2009. Product gross margin totaled $5.9 million and $14.1 million for the three and twelve months ended December 31, 2010, compared to gross margin of $1.2 million and gross deficit of $(0.2) million for the three and twelve months ended December 31, 2009. The Company reported a net loss of $9.8 million, or $0.16 per share, and $55.2 million, or $0.97 per share, for the three and twelve months ended December 31, 2010, compared to $11.5 million, or $0.25 per share, and $53.5 million, or $1.21 per share, for the three and twelve months ended December 31, 2009. The net loss for 2010 included $22.3 million in non-cash expenses, comprised primarily of share-based compensation, loss on debt extinguishment upon conversion of convertible notes, depreciation, and amortization.
Total cost of sales for the twelve months ended December 31, 2010 totaled $30.2 million compared to $26.0 million for 2009. The increase was primarily due to additional product sales offset by lower development expenses relating to our continuing performance obligations under development and collaboration agreements entered into during 2008. Research and development expense totaled $23.2 million in 2010 compared to $14.3 million in 2009. Changes in research and development expense included additional salaries and payroll related costs, share-based compensation, and facility costs. Selling, general and administrative expense totaled $40.5 million in 2010 compared to $35.2 million in 2009, with the change primarily due to additional selling, information technology, and international business development costs, including increased share-based compensation. As of December 31, 2010, the Company had $47.1 million in cash and marketable securities, and $1.7 million in restricted cash.
Conference Call
Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com under the investor webcast section and will be archived for future reference. To listen to the conference call, please dial (800) 447-0521 (US/Canada) or (847) 413-3238 (International) and use the participant code "28602160" approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients with diabetes and by healthcare providers in the hospital.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history. Successful commercialization and sale of the company’s products is subject to numerous risks and uncertainties, including product performance, a lack of acceptance in the marketplace by physicians and patients, the company’s inability to manufacture products in commercial quantities at an acceptable cost and quality level, possible delays in the company’s development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's annual report on Form 10-K for the period ending December 31, 2010, as filed with the Securities and Exchange Commission on March 3, 2011.
DexCom, Inc.
Consolidated Balance Sheets
(In thousands—except par value data)
As of December 31,
2010 2009
Assets
Current assets:
Cash and cash equivalents $ 4,889 $ 3,577
Short-term marketable securities, available-for-sale 42,224 24,439
Accounts receivable, net 6,671 3,490
Inventory 8,112 2,641
Restricted cash 1,439 —
Prepaid and other current assets 2,690 2,773
Total current assets 66,025 36,920
Property and equipment, net 10,763 6,422
Restricted cash 275 2,414
Other assets 101 1,192
Total assets $ 77,164 $ 46,948
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued liabilities $ 5,350 $ 5,745
Accrued payroll and related expenses 5,730 4,406
Current portion of long-term debt 525 900
Current portion of deferred revenue 3,524 7,745
Total current liabilities 15,129 18,796
Other liabilities 1,042 840
Long-term debt, net of current portion — 45,757
Total liabilities 16,171 65,393
Commitments and contingencies
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value per share, 5,000 shares authorized; no shares issued and outstanding at December 31, 2010 and December 31, 2009, respectively. — —
Common stock, $0.001 par value per share, 100,000 authorized; 62,360 and 62,078 shares issued and outstanding, respectively, at December 31, 2010, and 46,324 and 46,045 shares issued and outstanding, respectively, at December 31, 2009 62 46
Additional paid-in capital 407,375 272,730
Accumulated other comprehensive loss (66 ) (13 )
Accumulated deficit (346,378 ) (291,208 )
Total stockholders’ equity (deficit) 60,993 (18,445 )
Total liabilities and stockholders’ equity (deficit) $ 77,164 $ 46,948
DexCom Inc.
Consolidated Statements of Operations
(In thousands—except per share data)
Three Months Ended
December 31, Twelve Months Ended
December 31,
2010 2009 2010 2009
Product revenue
$
13,592
$ 6,632 $ 40,175 $ 18,036
Development grant and other revenue 2,044 3,839 8,456 11,657
Total revenue 15,636 10,471 48,631 29,693
Product cost of sales 7,664 5,478 26,104 18,216
Development and other cost of sales 983 886 4,084 7,816
Total cost of sales 8,647 6,364 30,188 26,032
Gross margin 6,989 4,107 18,443 3,661
Operating expenses
Research and development 6,902 4,172 23,227 14,294
Selling, general and administrative 9,973 9,397 40,506 35,200
Total operating expenses 16,875 13,569 63,733 49,494
Operating loss (9,886 ) (9,462 ) (45,290 ) (45,833 )
Other income (loss) 63 (17 ) 63 —
Interest income 22 48 95 354
Interest expense (8 ) (2,098 ) (1,548 ) (8,045 )
Loss on debt extinguishment upon conversion of convertible debt (3 ) — (8,490 ) —
Net loss ($9,812 ) ($11,529 ) ($55,170 ) ($53,524 )
Basic and diluted net loss per share ($0.16 ) ($0.25 ) ($0.97 ) ($1.21 )
Shares used to compute basic and diluted net loss per share 60,367 45,980 56,881 44,347
Interview: Mesoblast's Cephalon deal was late CEO's vision
By Bill Berkrot
NEW YORK | Wed Mar 2, 2011 6:19pm EST
NEW YORK (Reuters) - As Australia's Mesoblast Ltd (MSB.AX) works to bring the promise of stem cell therapy to a wide variety of illnesses and injuries, it is also advancing the vision of late Cephalon Inc (CEPH.O) CEO Frank Baldino.
Cephalon in December not only signed a major partnership deal with Mesoblast for a variety of potential therapies in cardiovascular and neurological areas, but it purchased a 20 percent stake in the company.
Cephalon founder and long-time Chief Executive Officer Baldino died in December at age 57 from complications associated with leukemia and was replaced by Chief Operating Officer Kevin Buchi. But it was Baldino who had set his sights on Mesoblast long before going on medical leave last August.
"Clearly Frank Baldino had been the driver of the original approach, so this was very much Frank's vision and baby and Kevin carried that forward," Graeme Kaufman, Mesoblast's senior vice president for finance and corporate strategy, told Reuters in an interview at the New York Stem Cell Summit on Tuesday.
"It's very sad indeed to lose one of those (industry) pioneers, but the whole negotiation went very smoothly and seamlessly," Kaufman said.
"I think for Cephalon this was a terrific deal because it gives them access to the whole new field of stem cell therapy, and I think they understand that it's kind of the next big thing," Kaufman said.
"It's a huge boost in general for cell-based therapies because it's really a substantial pharma company saying we think this field is really important," he added.
Many large pharmaceutical and biotechnology companies are linking up with tiny stem cell companies in hopes of getting a piece of what could be the next wave of innovative medical breakthroughs that their own labs have been unable to produce.
In December 2009, Athersys Inc (ATHX.O) got a huge vote of confidence when it signed a deal with Pfizer Inc (PFE.N), the world's largest pharmaceutical company.
Osiris Therapeutics Inc (OSIR.O), which looks to be on the verge of becoming the first stem cell company to turn therapeutic theory into an approved and marketed product, has a long-standing partnership with Genzyme Corp (GENZ.O).
Osiris Chief Executive Randal Mills joked at the Stem Cell Summit that he is "frantically learning French" now that his partner's new master will be Paris-based Sanofi-Aventis (SASY.PA).
"Osiris for us has been a good model. They've been through the regulatory pathway and it always helps to have somebody trailblazing," said Kaufman, who began his career as a biochemist for Australia's CSL Ltd (CSL.AX) before running CSL manufacturing and later becoming its chief financial officer.
"So I moved out to the dark side of finance," he quipped.
Mesoblast's finances, with the help of Cephalon, are in far better shape than those of many of its rivals.
Its market capitalization is about $1.5 billion. A chart at the Summit showed the combined market cap of 21 U.S. stem cell companies to be less than $2.5 billion
Mesoblast is hoping to complete midstage trials in heart failure patients by the middle of this year with an eye toward starting pivotal Phase III trials early next year.
Under that timeline Mesoblast and Cephalon could have a stem cell-based heart failure treatment on the market by 2015, Kaufman said.
"Our cash will keep us going for a long while," he said. "But we'll be investing heavily in diabetes, investing heavily in intervertebral disc repair. But now we have the resources to take those through ourselves," said Kaufman, explaining that Cephalon is responsible for funding expensive Phase III trials in the areas for which it has partnered.
"That frees us up entirely from the cardiovascular studies and the neurologic studies," he said.
The company works with adult stem cells derived from bone marrow known as mesenchymal precursor cells. Because they do not trigger an immune response, cells from one donor can be greatly expanded to treat many patients, giving Mesoblast potential therapies that could be sold like off the shelf medicines.
Mesoblast is discussing potential partnerships for other areas of therapy, but feels under no pressure to make a deal.
"We would probably still say that orthopedic will be a partnering opportunity, but we may not do that as soon as we otherwise would because we have the wherewithal to take it forward," Kaufman said.
The company will look for partners that can help Mesoblast expand global reach in marketing and distribution.
"That's what we did with Cephalon and it's probably what we'd look for in orthopedics," Kaufman explained.
"We're talking with all of the leaders in the orthopedic space. We could do a deal today if we wanted to."
(Reporting by Bill Berkrot, editing by Gerald E. McCormick)
______________________________________
(Comparison Note: a similar stem cell regenerative company, Pluristem, NASDAQ:PSTI has a current Market Cap of less than 100 million)
Agreed :)
Positive Pre-Clinical Data From Muscle Injury Study Moves Pluristem Toward Second Multi-Billion Dollar Clinical Indication
Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This study suggests that Pluristem's PLX cells have the potential to treat both accidental and intentionally induced muscle injuries.
Subject to regulatory approval, Pluristem plans on moving ahead with clinical trials for muscle injury indications. These trials will be conducted in addition to the anticipated Phase II/III trial using PLX-PAD for the treatment of Critical Limb Ischemia.
The data from the study indicates that PLX cells can be used in several categories of muscle injury, including accidental injuries, such as those incurred during athletic activity, as well as intentional injuries, such as after the incision of a skeletal muscle during surgery. These markets represent a potential annual market of approximately 10 Billion USD.
During the study, either immediately or seven days after delivering injury to the soleus muscle, PLX cells or saline were injected into the traumatized muscles. Four weeks after administration, the regenerative capacity of the soleus muscle was measured bilaterally by stimulating the sciatic nerve. PLX cell administration resulted in a significant improvement in the recovery of function of the involved muscles.
"This is a landmark study because it is the first to show significant improvement of muscle injuries through the use of placental derived allogenic therapies," said Prof. Dr. Georg N. Duda, head of the Julius Wolff Institute, co-head of the BCRT and principal investigator for the study. "The study demonstrates the great potential that Pluristem's PLX cells hold for treating such injuries and we look forward to continuing to research this application and investigate its positive effects even further."
Prof. Dr. Carsten Perka, head of orthopedics at the Center for Musculoskeletal Surgery at the Charite, emphasized the clinical need for this study: "A major problem for surgeons, especially in endoprosthetics, is muscular deficiencies, in particular muscular atrophy. Therefore, the approach of using PLX cells as adjuvant therapy to an orthopedic surgery is a unique opportunity to improve the healing outcome of patients."
Based on the pre-clinical studies, Pluristem has initiated discussions with the Paul Ehrlich Institute (PEI), the German competent authority, for a clinical development plan in which PLX cells will be used as an adjuvant therapy for the recovery of muscle function following hip replacement surgery.
"The successful completion of these pre-clinical studies is very exciting for Pluristem, as it opens an additional, and potentially very lucrative, product candidate in our PLX platform pipeline," said Zami Aberman, Chairman, President and CEO of Pluristem. "We are very encouraged by the findings of the Berlin-Brandenburg Center for Regenerative Therapies and look forward to moving ahead with the next stage of clinical research."
About Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
The BCRT has a highly interactive research program based on a consortium of internationally acknowledged experts in both basic and clinical science - with a track record of successful scientific interaction, demonstrated by numerous joint publications in high-ranking journals and joint network projects (DFG, BMBF, EU etc.). The program comprises work in three medical research fields linked to overlapping platforms on basic, biomaterials, and translational research. The center places emphasis on research and clinical programs related to musculoskeletal, immunological and cardiovascular applications, since these aspects of regenerative medicine are most advanced at the Charite and are closest to clinical translation. Partnerships have already been established with several companies, including Milteny Biotech, BBraun, Pharmicell Europe and Pluristem. For more information visit http://bcrt.charite.de/
The Berlin-Branenburg Center for Regenerative Therapies logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8821
About Pluristem Therapeutics
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration. The PLX-PAD comprehensive clinical development plan has been recognized by both the EMA and FDA, targeting a sub-population of 20 million patients in the Peripheral Artery Disease (PAD) market.
Data from two Phase I clinical trials indicate that Pluristem's first PLX product, PLX-PAD, is safe and potentially effective for the treatment of end stage PAD. Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically.
Pluristem has a strong patent portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release. Follow Pluristem on Twitter @Pluristem.
CLICK HERE to watch a video where CLI patients and doctors involved with the clinical trials share their stories. CLICK HERE to see Pluristem's cell therapy product animation on YouTube.
The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward looking statements when we discuss the research conducted at Berlin-Brandenburg Center for Regenerative Therapies and Charité University of Medicine and say that it offers new potentially promising cell treatment for Muscle Injury Market, or that our PLX cells have the potential to treat both accidental and intentionally induced muscle injuries, or that subject to regulatory approval, we plan on moving ahead with clinical trials for the muscle injury indication, or that the data from the study indicates that PLX cells may be used in several categories of muscle injury, including accidental injuries, such as those incurred during athletic activity, as well as intentional injuries, such as after the incision of a skeletal muscle during surgery and that these markets represent a potential annual market of approximately 10 Billion USD. or when the said study is described as a landmark study and it is said that it demonstrates the potential that Pluristem's PLX cells hold for treating such injuries, or when it is said that the approach of using PLX cells as adjuvant therapy to an orthopedic surgery is a unique potential opportunity to improve the healing outcome of patients, or when we say that the successful completion of these pre-clinical studies potentially opens an additional, and potentially very lucrative, product candidate in our PLX platform pipeline, or that we look forward to moving ahead with the next stage of clinical research. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
CONTACT: Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
Charite - Universitatsmedizin Berlin, Campus Virchow-Klinikum
Augustenburger Platz 1, SudstraBe 2,
13353 Berlin, Germany
Media Contact:
Stephanie Benusch
+49 30 450 552 096
Stephanie.Benusch@charite.de
Pluristem Therapeutics Inc.
William Prather R.Ph., M.D.
Sr. VP Corporate Development
1-303-883-4954
William.PratherMD@pluristem.com
Media Contact:
Matthew Krieger
Ruder Finn - for Pluristem
+972-54-467-6950
matthew@ruderfinn.co.il
Another 52 week high.
Closed at $1.38 HOD - Board sure is quiet - lol
Looks like a gapper tomorrow?
The FDA and Slower Cures
The bureaucratic assault on cancer treatments.
The White House now claims it is so alarmed about declining private pharmaceutical research that the government must create a new multibillion-dollar R&D center. Perhaps it should consult the Food and Drug Administration, which thinks it is approving too many new drugs, especially for serious diseases like cancer.
That's the message of this month's remarkable FDA hearing to grill six major drug makers on the alleged shortcomings of the "accelerated approval" process. Congress created this fast-track for promising drugs for unmet medical needs in 1992, but the FDA bureaucracy thinks it is too friendly to industry.
The FDA is about to withdraw Avastin as a treatment for women with terminal breast cancer, and then there's a drug that most readers probably haven't heard of, called pixantrone. Like Avastin, its story reveals an agency that cares more about its regulatory prerogatives than about the thousands of patients who might benefit and will die waiting.
In May 2010, the FDA rejected pixantrone for treating non-Hodgkin's lymphoma, a blood cancer that kills nearly 12,000 Americans a year. The agency's veto came not because pixantrone failed in a clinical trial—in fact, it was a qualified success. Instead, the FDA determined that the trial was not "flawlessly executed," as its regulations demand.
If perfection is the standard for new cancer drugs, then we may as well give up hope of ever getting another one. As destructive, the FDA went out of its way to railroad pixantrone and make an example of the drug's maker, Cell Therapeutics, in order to send another warning to the drug industry to jump through the right bureaucratic hoops.
Pixantrone is targeted to patients with aggressive non-Hodgkin's lymphoma who have already received two or more chemotherapy treatments. There is little recourse left for these patients. If disease returns, most receive palliative care, with life expectancy measured in weeks or months. The conventional drugs, called anthracyclines, cause cumulative heart damage that prevents further use.
Pixantrone is a next-generation anthracycline designed to be more effective and less toxic, allowing patients to continue therapy for longer. A Phase III randomized trial, the most rigorous kind, began in 2004: Patients either received pixantrone or were entered into a control arm where they received their physician's choice of existing therapies. The study tested "complete responses," or the disappearance of all signs of cancer. (That does not mean the disease has been cured.)
Incredibly, 20% of patients receiving pixantrone showed a complete response, versus only 6% in the control arm. That rose to 24% versus 7% in a follow-up analysis. The data also show a trend toward overall survival, even if it was not statistically significant. These are unheard-of results for end-stage patients with very poor prognoses.
Yet even more incredibly, the FDA declined to approve pixantrone, despite these clinically meaningful results. Here's the key reason, according to an FDA briefing document: "The study was not stopped at a planned interim analysis and early study stopping invalidated the applicant's Special Protocol Assessment."
To translate from the jargon, a Special Protocol Assessment is an agreement between the FDA and a drug maker about how a clinical trial should be run. Cell Therapeutics initially planned to enroll 320 patients in 36 months. However, it stopped the trial early, after recruiting 140 patients in 45 months.
This is not unusual. Some 60% of Phase III trials, including those conducted by the National Institutes of Health, do not accept as many patients as originally projected. Modern statistical science is designed to adapt to such unforeseen realities.
In this case, enrollment was hobbled because pixantrone wasn't a "sexy" drug—in 2004, there was minimal data about its effectiveness and thus minimal interest from U.S. oncologists or hematologists. More important, though, was the trial design. Only the most desperate patients will enroll in the hopes of getting an experimental drug if that means a one in two chance of ending up with a treatment doctors know is unlikely to work.
Randomized trials are the FDA gold standard, and at the accelerated approval hearing most of the FDA panelists said such trials should be the default position for oncology. But a cancer drug isn't another cholesterol pill, and, thankfully, FDA regulations do not formally require them in all circumstances.
The FDA encourages companies to conduct multiple single-arm studies in lieu of randomization, but this is only done for the most promising drugs that can justify the investment in trials that cost tens of millions of dollars apiece. For drugs like pixantrone, where success is less certain and budgets are limited, even large drug makers will run a single controlled trial—so that if the drug does succeed, it complies with FDA regulations. If a drug is approved on a single trial, it must be so "well designed" and "flawlessly executed" that "a second trial would be ethically or practically impossible to perform."
***
The real ethical problem here is what is essentially the FDA's rigid protocol mandate even for experimental drugs for terminal illnesses. A major debate erupted last year over the Roche drug PLX4032 for advanced melanoma, which had to continue a trial even though it is an historic medical breakthrough: Doctors described a "Lazarus effect" from the drug, even as control patients died amid obviously ineffective standard therapies.
The Catch 22 is that if a trial deviates from protocol, even with such impressive real-world results, it becomes more difficult to generate the "proof" beyond any doubt that the FDA requires. Protocol violations are punished: The FDA sat on the colon cancer treatment Erbitux for years because it was a case of "good drug, bad development plan," as cancer drugs chief Richard Pazdur put it at a Congressional hearing in 2002.
Dr. Pazdur similarly sandbagged pixantrone. Not only did Cell Therapeutics violate protocol by stopping the trial early, but it tried to use accelerated approval.
At an advisory panel meeting, Dr. Pazdur repeatedly stated that the meeting's goals were larger than merely the merits of this one drug. In his opening comments, he declared that "Accelerated approval is not a salvage mechanism for failed trials or marginal drugs." Later, discussing a technical detail of pixantrone's trial design, he emphasized that "I think we as an oncology community have to get that point across to drug developers, because we will continually have applications with very marginal results."
His excuse for rejecting pixantrone was that original Special Protocol Assessment. Ordinarily, a trial is unblinded around the half-way point for an interim analysis, which introduces error into the results and thus requires a more stringent standard of statistical proof in the final analysis to control for false positives. Amid its enrollment problems, Cell Therapeutics never unblinded the trial, and thus did not introduce error, merely skipping ahead to the final analysis.
Dr. Pazdur nonetheless required pixantrone to adhere to the Special Protocol and hit the final, more stringent standard of proof, as if the facts from the trial hadn't changed. This gambit reduced the 24% complete response rate to statistical insignificance, which was the basis for the FDA's rejection. In December, Cell Therapeutics took the exceedingly rare step of appealing the decision through a formal FDA process, which companies almost never do for fear of bureaucratic reprisals. The appeal claims Dr. Pazdur "diverged from accepted statistical principles," and a decision is due soon.
The larger issue is the FDA's regulatory method. Data can always be better, and pixantrone's were messier than the FDA favors—even if the agency hadn't required a higher standard of proof. The issue is that messy data aren't a good reason, and certainly not an ethical one, for delaying approval of a drug like pixantrone.
Most medicines demonstrate their true benefits (or lack thereof) in clinical settings, outside of the artificial confines of randomized trials, where doctors discover and refine uses far beyond what the FDA envisions when it sets protocol. In the early 1990s, the FDA was politically forced to let AIDS drugs into the hands of patients and doctors who collected data from actual medical practice. That kind of flexibility was far more successful than the current cancer status quo, in which patients die until the FDA seal of approval eventually arrives.
***
Cell Therapeutics is now mounting another trial to gather more data, and enrollment is likely to be rapid given the intense interest the original trial has generated. But it could be years before pixantrone comes to market—and years more before doctors know if the drug is a real breakthrough for non-Hodgkin's lymphoma, given that it is only being tested with the sickest patients.
The wonder is how the Administration can wonder why there aren't enough new medicines, even as the FDA rolls back accelerated approval. The reason is that the agency regards drug makers as adversaries that must be punished, not partners in the anticancer fight. The real victims are the patients with no attractive options who needlessly suffer when the government delays drugs like pixantrone.
http://online.wsj.com/article/SB10001424052748703766704576009512990553104.html
52 week high today
ok - thanks for your take on it.
NNVC update...
It has something for everyone: story stock that has an excellent chance to be a zipcode changer in the next year or two and the chart is set for blast off plus 2 million shares are short so it could also be the MOASS.
The latest short data on NNVC shows over 2 million shares short?
Will these FINRA changes impact NNVC next week?
http://www.finra.org/Industry/Regulation/RuleFilings/2010/P121892?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+FINRARuleFilings+(FINRA+Rule+Filings)
Well it was up 50-100% for most of the year and the story is not over yet but I understand the rules.
The latest short data on NNVC shows over 2 million shares short?
Will these FINRA changes impact NNVC next week?
http://www.finra.org/Industry/Regulation/RuleFilings/2010/P121892?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+FINRARuleFilings+(FINRA+Rule+Filings)
If you do not have a margin account or if you never use the margin, then call your broker and also state it in a fax (in writing) that you do not want your NNVC shares loaned out under any circumstance and it could get interesting really quick.
This stock is a prime candidate for the MOASS, IMHO BWDIK :)
I have not heard of NASDAQ as a near term goal? Get the INDA/TOX done and if there are no issues then the price will take care of itself. When the price is in the range to uplist, then add the other "mouths to feed" and uplist. IMHO
It is wise to be frugal at this stage until they have proven that they have something special that they can get to the FDA. This has been a longer process than anticipated by all who want to see this company succeed and it is good that they have not gotten the cart before the horse, again IMHO.
Any updates on the ITRO (itronics) case? It is hard to bet against the NIR groups record in these types of lawsuits. If NIR wins, could ITRO leave bagholders in the wind and use all their partnerships and "spins offs" to "protect" their technology?
k - thanks for sharing.
So did he say anything? Are we delayed (again) or are we toast? It was my understanding that MTRE has valuable carryover tax losses (20 million dollars?) to bring into any deal so even the "shell" has value if they can find the right buyer?
So for full disclosure (since you admit to being short NNVC) would you mind stating that your other two companies would not be impacted in any way if any of Nanoviricides drug candidates are approved?
NNVC closed at $1.16 - it may not be for the short-term traders but I believe if you add this as my 4th no-brainer, a year from now you will very pleased.
PSTI @ $2.71 - would be my 5th no-brainer pick if I could add additional picks and again this is a long-term pick as I am not a day trader.
PS very happy with my current no-brainers APNT & BLTI and believe that they are just getting started for long-term multi-year growth.. MTRE is in a transition and it could jump hard if the deal gets done.
I have been holding too and hope to add more at these levels but if it takes off and runs hard that is also ok with me:)
Question for everyone on the Board: Who has been using their products and for how long and how much weight have you lost/gained ?
I'm glad to see that they have finally taken my advice and are replacing the artificial sweeteners and are using stevia in some of their products. I may have to try it now.
"Energy drinks" are starting to get targeted as health risks and CELH needs make sure they are not caught up in the backwash.
So exactly what has changed since you posted this?
Ok - I stand corrected. I was thinking of the recent financing statement:
How can you say that "we're" are all in trouble? Trading NNVC and joining the herd who may sell it next week will not affect NNVC's plan now that they have the cash to proceed for a couple of years on their own and if they do choose to do a deal it will be from a position of strength on their terms. IMHO this could be the best time to buy and hold in the history of NNVC (from a price-time percentage viewpoint) regardless of what the stock price does next week or next month. As a student of "Story" stocks for many years, it seems like they all go through a similar phase where many of the "longs" give up right before a stock takes off. I don't have the time or desire to watch the market every second so I believe I will be happy with the price of my current buys when compared to next year at this time, BWDIK. Never invest more than you can afford to loose because this is highly speculative.
Hop Hop Hop? lol
Bought more NNVC today at $1.15
Applied Nanotech Announces Strategic Relationship with Sichuan Anxian Yinhe Construction and Chemical Group Co. Ltd ("YHCC")
YHCC is Granted Option to Key Technologies.
YHCC Makes Strategic Investment in Applied Nanotech
Austin, TX - February 17, 2011 – Applied Nanotech Holdings, Inc. (OTC BB: APNT) is pleased to announce that it has formed a strategic relationship with Sichuan Anxian Yinhe Construction and Chemical Group Co., Ltd (“YHCC”). The companies signed a letter of intent, giving YHCC the exclusive right to license and commercialize two of APNT’s technologies. Any licenses signed will be exclusive in China and other specific parts of Asia, and nonexclusive for the rest of the world. This right is valid until August 31, 2011, and can be extended further upon mutual agreement of the parties. YHCC is providing APNT with a deposit, for this exclusive right, which will be applied against the upfront payment on the two licenses, if and when completed.
YHCC has expressed a strong interest in licensing additional technologies from APNT, after successful conclusion of the first two, with the ultimate goal of commercializing or representing all APNT technologies in China.
In addition to the letter of intent, YHCC is making a strategic investment of $2.5 million in APNT, for which it will receive 6,578,948 shares of restricted common stock and a board seat on APNT’s Board of Directors. Terms were agreed upon in January 2011 with final documents signed on February 13, 2011 in Mianyang, China. The share price of $0.38 was based on the market price of APNT’s common stock at the time the terms of the agreement were reached.
“Along with their strong interest in licensing our technology, YHCC’s strategic investment clearly demonstrates both their commitment and confidence in our technologies. With YHCC, we believe we have found the right partner in China with the financial resources and know-how to help us commercialize our technology,” commented Dr. Zvi Yaniv, CEO of Applied Nanotech, Inc.
Founded in 1965, YHCC has a history of over 40 years of successful manufacturing and commercialization of products. YHCC is a diversified construction, manufacturing and chemical company, and is now China’s largest suppliers of chromium salts, including Sodium Dichromate, Chromic Acid, Chrome Sulfate, Chromic oxide, and others. Located in the Sichuan Province and operating state of the art facilities, YHCC also has significant operations in cement manufacturing, the production of sulphuric acid, as well as the production of nutritional supplements and feed additives. YHCC has assets of 1.56 billion Yuan ($250 million), over 2000 employees, and, in 2010, YHCC’s revenue exceeded 2 billion Yuan ($330 million), up 100 % from its 2007 level of $1 billion Yuan, and expects to see similar growth levels in the coming years. YHCC is an innovative and entrepreneurial company operating 3 industrial parks, with plans to further expand into high tech areas, including nanotechnology.
“We are thrilled to have found a partner like YHCC in China,” stated Doug Baker, Chief Executive Officer of Applied Nanotech Holdings, Inc. “Their commercialization expertise is a perfect match with our technology and we strongly believe that we will receive substantial financial and strategic benefits from having YHCC as a long-term partner. We are pleased that they have expressed an interest in investing in APNT and being on our Board of Directors, which demonstrates their intention of being a long- term shareholder, and recognition of the significant value a long-term relationship can create.”
“After searching top R&D companies around the world, we made the careful decision to partner with APNT,” said Xianrong LI, Chairman and CEO of YHCC. “We are confident that our skills in commercialization, combined with APNT’s technologies, give us the right combination of talents to deliver significant long-term value to both our organizations.”
ABOUT SICHUAN ANXIAN YINHE CONSTRUCTION AND CHEMICAL GROUP CO., LTD (“YHCC”)
Located in Anxian County, near Mianyang in Sichuan Province, China, YHCC currently operates through 9 separate subsidiaries located in three specialized industrial parks, occupying over 3000 acres (700 US acres). YHCC’s website is http://www.yinhejituan.com/en.
About APPLIED NANOTECH HOLDINGS, INC.
Applied Nanotech Holdings, Inc. is a premier research and commercialization organization focused on solving problems at the molecular level. Its team of PhD level scientists and engineers work with companies and other organizations to solve technical impasses and create innovations that will create a competitive advantage. The business model is to license patents and technology to partners that will manufacture and distribute products using the technology. Applied Nanotech has over 250 patents or patents pending. Applied Nanotech’s website is www.appliednanotech.net.
Safe Harbor Statement
This release contains forward-looking statements that involve risks and uncertainties concerning our business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in our annual report on Form 10-K for the fiscal year ended December 31, 2009, and in reports subsequently filed by us with the Securities and Exchange Commission ("SEC"). All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval System (EDGAR) at www.sec.gov or from our website listed above. We hereby disclaim any obligation to publicly update the information provided above, including forward-looking statements, to reflect subsequent events or circumstances.
Company Contact:
Doug Baker
Applied Nanotech Holdings, Inc.
248.391.0612
dbaker(at)appliednanotech.net
Pluristem Therapeutics Inc. (PSTI) is “One to Watch”
By QualityStocks | February 15, 2011 7:30 AM EST
Founded in 2001, Pluristem Therapeutics is a bio-therapeutics company that lists on the NASDAQ Capital Market. The Company is dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic, and autoimmune disorders. The (PLacental eXpanded) cell products are stored off-the-shelf, ready-to-use, and require no histocompatibility matching.
PLX cells are the ASCs expanded in Pluristem’s proprietary (PluriX™) 3D bioreactor. PLX cells are immune privileged, possess immunomodulatory properties, and are expanded in vitro without showing signs of phenotypic or karyotypic changes. Pluristem Therapeutics believes that the PLX cells’ mechanism of action may be related to the secretion of cytokines and/or other potent immune modulators.
The Company’s first product, PLX-PAD, is designed to treat Peripheral Artery Disease. PLX-PAD received from the Food and Drug Administration (FDA) and the Paul Ehrlich Institute (PEI), the German competent authority in the European Union, clearance to begin a “First-In-Human” placental-derived mesenchymal-like stromal cell clinical trial.
PLX-PAD has undergone development as an unrelated donor-patient (allogeneic) product intended to treat the limb ischemia from Peripheral Artery Disease (PAD). In the United States alone, it is estimated that 8 to 12 million people suffer from limb ischemia.
Pluristem Therapeutics Inc.’s pre-clinical product line-up includes PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis.
http://www.ibtimes.com/articles/112748/20110215/pluristem-therapeutics-inc-psti-is-one-to-watch.htm
I would have agreed with you a few months ago before the "High Plains" deal. I have been in and out of this one a few times but now it look like the time to buy with the price holding $.10 new cash and the stock swap that I take to mean "High Plains" will be using the BCTE technology to recover wells that they could not recover otherwise. If the price of natural gas goes up or environmental standards force drillers to change their habits then BCTE will benefit and it is thinly traded and moves quickly. IMHO
added at $1.18 & $1.19 today
Northwest Biotherapeutics to Present at BIO CEO & INVESTOR CONFERENCE
Northwest Bioth New (OTCBB:NWBO)
Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that its Chair of the Board of Directors, Ms. Linda Powers, will give a corporate presentation at the 13th Annual Biotechnology Industry Organization's BIO CEO & Investor Conference being held February 14th, 2011 at 2:00 pm in the Conrad Room of the Waldorf Astoria Hotel in New York City.
Ms. Powers will provide a corporate and clinical update, including an update on NWBT's DCVax® therapeutic cancer vaccine for Glioblastoma multiforme, which is in a Phase II, randomized, double blinded, placebo controlled clinical trial. The update will include the striking long-term follow-up data from prior trials, the lack of toxicity, the ease of administration, the relatively low cost, the multi-product pipeline, and the high-yield manufacturing process for the Company's DCVax® cancer vaccine. The presentation will be web cast and can be accessed using: http://www.veracast.com/webcasts/bio/ceoinvestor2011/44110196.cfm
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company is developing dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.
For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics
Mesoblast Limited Issues Shares To Cephalon International Holdings Inc; Exercises Options
2:45am EST
Mesoblast Limited announced that it has issued 25,292,056 fully paid ordinary shares. The Company exercised 320,000 options at AUD 2.13 per share, 160,000 options at AUD 0.96 per share, 50,000 options at AUD 1.58 per share, and 60,000 options at AUD 1.00 per share. The Company has also issued 24,702,056 ordinary shares at AUD 4.35 to Cephalon International Holdings Inc as approved by shareholders on February 9, 2011.
I would like your opinion on PSTI if you have a chance. Thanks
Cord Blood America Announces Special Shareholder Meeting
Last update: 2/10/2011 4:03:00 PM
LAS VEGAS, Feb. 10, 2011 /PRNewswire via COMTEX/ -- Cord Blood America, Inc. () (CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today a Special Meeting of its shareholders on April 21, 2011 to consider a proposal to effect a reverse stock split of one share for each 500 outstanding shares and then proportionally increase authorized shares.
"We are asking for our investors' support at this critical point in the Company's growth. Approval of this measure will assist in our efforts to make Cord Blood America a financially stronger company," Mr. Schissler said. "From 2007 to 2010, Cord Blood America was able to aggressively reduce its principal debt obligation by more than $8 million. This was a necessary and critical step and markedly improved our balance sheet. Please note the dramatic graph linked to this news release demonstrating the impact of our debt reduction. There are tremendous opportunities in our future, and we need to take this next step towards our path to profitability. We are asking our investors to help CBAI seize these opportunities."
"The Board of Directors believes that implementing a reverse stock split may increase the market price for CBAI common stock as fewer shares will be outstanding," said Matthew Schissler, CEO and co-founder. "It also believes that the reverse split may encourage future interest and trading in CBAI common stock."
"Additionally, our current cap structure limits strategic long term investment assisting in our acquisition program as well as other growth initiatives. We've had a great run on raising capital, but our future endeavors require a tighter capitalization," Mr. Schissler said. "We believe this may also assist the Company in its long term goal for placement on a more prestigious stock exchange."
Proxy information on voting is being distributed in a Schedule 14A filing available at . Shareholders of record on March 10, 2011 may vote their proxy.
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at . For investor information, visit .
Safe Harbor: This press release contains forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned that such forward looking statements should not be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained herein will in fact occur.These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in its Form 10-K and in the Company's other reports filed with the Securities and Exchange Commission that discuss certain of the risks and factors that may affect the Company and its business.
CONTACT:Paul KnopickE & E Communications949/707-5365pknopick@eandecommunications.com
SOURCE Cord Blood America, Inc.
Copyright (C) 2011 PR Newswire. All rights reserved
$4.36 was a good call :) It hit another 52 week high today ($6.30 so far).
"Google Ventures, the investment fund that Google started last year, is getting into vacation rentals."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=56091674
BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading Dental Laser company, announced today that it has raised approximately $4.65 million to-date through the sale of 1.5 million shares of its common stock (without warrants or options attached) under its Controlled Equity Offering Agreement to various institutions and retail investors in the open market at an average of $3.10 per share. BIOLASE has used a portion of these proceeds to pay off its remaining balance for the Loan and Security Agreement with MidCap Funding III, LLC and Silicon Valley Bank. The final payment included the remaining principal of $2.6 million, accrued interest of approximately $30,000 and fees and expenses of approximately $169,000. The debt facility, established by previous management, had an effective interest rate of approximately 34 percent.
Chairman and CEO Federico Pignatelli stated, "The recent financial transactions considerably improve our balance sheet by eliminating this high-cost debt and restoring a healthy level of capital. In addition to paying off this debt, we believe the newly raised capital, along with existing cash, is adequate to fund our growth initiatives and meet all of our current operating obligations. We also believe that BIOLASE, with its improved financial strength and expected positive operating results in the first quarter, will achieve a sufficient level of net positive equity to apply for an upgrade to its listing from the current NASDAQ Capital Market to the prestigious NASDAQ Global Market."
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading Dental Laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact:
Jill Bertotti
Allen & Caron
+1-949-474-4300
I have no idea on the timing. After I find a company that looks like it has a good change to actually make it in the market place (usually after severe beatings to former shareholders) then I just try to estimate the right "season" and then do a little chart work before I make a call. I am actually pleased if I'm within 10-20 percent of the bottom and depending on my level of confidence, I will sometimes average up or down from that point or sell if the stock moves down on high volume. I don't have problems waiting a few months as long as the stock is holding and no other issues arise but sometimes I get lucky and they just take off like crazy right away.
Applied Nanotech to Exhibit Its Carbon Nanotube-Based Composites and Materials at nano tech 2011, the International Nanotechnoloy Exhibition & Conference.
Applied Nanotech Holdings, Inc. (OTCBB:APNT) is pleased to announce that it will showcase its new carbon nanotube-based composites and materials, which have been shown to dramatically improve the performance of golf clubs and racquets, at nano tech 2011, the 10th International Nanotechnology Exhibition & Conference. The conference will be held from February 16-18, 2011 in Tokyo, and is the largest show of its kind with 50,000 participants anticipated. Applied Nanotech will be at booth #E-16.
On display at the Applied Nanotech Booth, will be its new carbon nanotube-based composites, which have the ability to provide improved mechanical strength for sporting goods equipment and windmill blades. Applied Nanotech developed these composites in conjunction with Japanese sporting goods giant, Yonex, for golf clubs and badminton racquets. After achieving significant product testing results with improvements of 14 percent, 21 percent, and 24 percent, in flexural strength (bending strength), flexural modulus (stiffness) and impact strength (addressing external shock) respectively, compared to conventional carbon materials, Yonex is introducing golf clubs and badminton racquets using this new composite, under the tradename, Nanopreme™, will be for sale in February and March 2011, respectively.
Applied Nanotech will also be exhibiting materials for high thermal conduction with low density (light weight), metallic nanoparticle inks and pastes for printed electronic applications, transparent conductors and solar cell production (energy harvesting), as well as other technologies.
For more information about the conference and expo, visit: http://www.nanotechexpo.jp/en/.
ABOUT APPLIED NANOTECH HOLDINGS, INC.
Applied Nanotech Holdings, Inc. is a premier research and commercialization organization focused on solving problems at the molecular level. Its team of PhD level scientists and engineers work with companies and other organizations to solve technical impasses and create innovations that will create a competitive advantage. The business model is to license patents and technology to partners that will manufacture and distribute products using the technology. Applied Nanotech has over 300 patents or patents pending. Applied Nanotech's website is http://www.appliednanotech.net.
SAFE HARBOR STATEMENT
This press release contains forward-looking statements that involve risks and uncertainties concerning our business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in our annual report on Form 10-K for the fiscal year ended December 31, 2009, and in reports subsequently filed by us with the Securities and Exchange Commission ("SEC"). All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval System (EDGAR) at www.sec.gov or from our website listed above. We hereby disclaim any obligation to publicly update the information provided above, including forward-looking statements, to reflect subsequent events or circumstances.
CONTACT: Doug Baker
Applied Nanotech Holdings, Inc.
248.391.0612
dbaker@appliednanotech.net